Zimmermann J, Friedli N, Bavato F, Stampfli P, Coray R, Baumgartner M
Neuroimage Clin. 2022; 36:103191.
PMID: 36126513
PMC: 9486575.
DOI: 10.1016/j.nicl.2022.103191.
Pantoni M, Anagnostaras S
Pharmacol Rev. 2019; 71(3):413-449.
PMID: 31249067
PMC: 6607799.
DOI: 10.1124/pr.118.017087.
Wunderli M, Vonmoos M, Treichler L, Zeller C, Dziobek I, Kraemer T
Int J Neuropsychopharmacol. 2017; 21(4):333-344.
PMID: 29087534
PMC: 5888715.
DOI: 10.1093/ijnp/pyx098.
Bershad A, Miller M, de Wit H
Psychopharmacology (Berl). 2017; 234(14):2159-2166.
PMID: 28432376
PMC: 5984654.
DOI: 10.1007/s00213-017-4621-x.
Kuypers K, Theunissen E, van Wel J, de Sousa Fernandes Perna E, Linssen A, Sambeth A
PLoS One. 2016; 11(2):e0149438.
PMID: 26907605
PMC: 4764468.
DOI: 10.1371/journal.pone.0149438.
Mechanisms and environmental factors that underlying the intensification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced serotonin syndrome in rats.
Tao R, Shokry I, Callanan J, Adams H, Ma Z
Psychopharmacology (Berl). 2014; 232(7):1245-60.
PMID: 25300903
PMC: 4361258.
DOI: 10.1007/s00213-014-3759-z.
Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
Taurah L, Chandler C, Sanders G
Psychopharmacology (Berl). 2013; 231(4):737-51.
PMID: 24114426
DOI: 10.1007/s00213-013-3288-1.
Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users.
Bosch O, Wagner M, Jessen F, Kuhn K, Joe A, Seifritz E
PLoS One. 2013; 8(4):e61234.
PMID: 23585882
PMC: 3621736.
DOI: 10.1371/journal.pone.0061234.
Perceived risk associated with ecstasy use: a latent class analysis approach.
Martins S, Carlson R, Alexandre P, Falck R
Addict Behav. 2011; 36(5):551-4.
PMID: 21296504
PMC: 3049947.
DOI: 10.1016/j.addbeh.2011.01.013.
The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.
Steinkellner T, Freissmuth M, Sitte H, Montgomery T
Biol Chem. 2011; 392(1-2):103-15.
PMID: 21194370
PMC: 4497800.
DOI: 10.1515/BC.2011.016.
Differential effects of ecstasy on short-term and working memory: a meta-analysis.
Nulsen C, Fox A, Hammond G
Neuropsychol Rev. 2010; 20(1):21-32.
PMID: 20157852
DOI: 10.1007/s11065-009-9124-z.
Depressive and anxiety symptomatology in ecstasy users: the relative contribution of genes, trauma, life stress and drug use.
Scott R, Hides L, Allen J, Burke R, Lubman D
Psychopharmacology (Berl). 2010; 209(1):25-36.
PMID: 20101393
DOI: 10.1007/s00213-009-1763-5.
Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humans.
Freeman T, Morgan C, Klaassen E, Das R, Stefanovic A, Brandner B
Psychopharmacology (Berl). 2009; 206(4):563-73.
PMID: 19436994
DOI: 10.1007/s00213-009-1564-x.
Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes.
Parrott A, Lock J, Conner A, Kissling C, Thome J
Neuropsychobiology. 2008; 57(4):165-80.
PMID: 18654086
PMC: 3575116.
DOI: 10.1159/000147470.
Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users.
Hanson K, Luciana M, Sullwold K
Drug Alcohol Depend. 2008; 96(1-2):99-110.
PMID: 18384979
PMC: 2492887.
DOI: 10.1016/j.drugalcdep.2008.02.003.
Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users.
Parrott A, Milani R, Gouzoulis-Mayfrank E, Daumann J
J Neural Transm (Vienna). 2007; 114(8):959-68.
PMID: 17520319
DOI: 10.1007/s00702-007-0715-7.
Acute and chronic effects of ketamine upon human memory: a review.
Morgan C, Curran H
Psychopharmacology (Berl). 2006; 188(4):408-24.
PMID: 17006715
DOI: 10.1007/s00213-006-0572-3.
Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy").
Quednow B, Kuhn K, Hoppe C, Westheide J, Maier W, Daum I
Psychopharmacology (Berl). 2006; 189(4):517-30.
PMID: 16425060
DOI: 10.1007/s00213-005-0256-4.
Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.
Verdejo-Garcia A, Lopez-Torrecillas F, Gimenez C, Perez-Garcia M
Neuropsychol Rev. 2004; 14(1):1-41.
PMID: 15260137
DOI: 10.1023/b:nerv.0000026647.71528.83.
Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity.
Parrott A
Psychopharmacology (Berl). 2004; 173(3-4):234-41.
PMID: 15007594
DOI: 10.1007/s00213-003-1712-7.